skip to main content


Title: Bayesian Treatment Screening and Selection Using Subgroup-Specific Utilities of Response and Toxicity
Abstract

A Bayesian design is proposed for randomized phase II clinical trials that screen multiple experimental treatments compared to an active control based on ordinal categorical toxicity and response. The underlying model and design account for patient heterogeneity characterized by ordered prognostic subgroups. All decision criteria are subgroup specific, including interim rules for dropping unsafe or ineffective treatments, and criteria for selecting optimal treatments at the end of the trial. The design requires an elicited utility function of the two outcomes that varies with the subgroups. Final treatment selections are based on posterior mean utilities. The methodology is illustrated by a trial of targeted agents for metastatic renal cancer, which motivated the design methodology. In the context of this application, the design is evaluated by computer simulation, including comparison to three designs that conduct separate trials within subgroups, or conduct one trial while ignoring subgroups, or base treatment selection on estimated response rates while ignoring toxicity.

 
more » « less
NSF-PAR ID:
10486021
Author(s) / Creator(s):
; ;
Publisher / Repository:
Oxford University Press
Date Published:
Journal Name:
Biometrics
Volume:
79
Issue:
3
ISSN:
0006-341X
Format(s):
Medium: X Size: p. 2458-2473
Size(s):
p. 2458-2473
Sponsoring Org:
National Science Foundation
More Like this
  1. Summary

    A salient feature of data from clinical trials and medical studies is inhomogeneity. Patients not only differ in baseline characteristics, but also in the way that they respond to treatment. Optimal individualized treatment regimes are developed to select effective treatments based on patient's heterogeneity. However, the optimal treatment regime might also vary for patients across different subgroups. We mainly consider patients’ heterogeneity caused by groupwise individualized treatment effects assuming the same marginal treatment effects for all groups. We propose a new maximin projection learning method for estimating a single treatment decision rule that works reliably for a group of future patients from a possibly new subpopulation. Based on estimated optimal treatment regimes for all subgroups, the proposed maximin treatment regime is obtained by solving a quadratically constrained linear programming problem, which can be efficiently computed by interior point methods. Consistency and asymptotic normality of the estimator are established. Numerical examples show the reliability of the methodology proposed.

     
    more » « less
  2. A Bayesian phase I‐II design is presented that optimizes the dose of a new agent within predefined prognostic subgroups. The design is motivated by a trial to evaluate targeted agents for treating metastatic clear cell renal carcinoma, where a prognostic risk score defined by clinical variables and biomarkers is well established. Two clinical outcomes are used for dose‐finding, time‐to‐toxicity during a prespecified follow‐up period, and efficacy characterized by ordinal disease status evaluated at the end of follow‐up. A joint probability model is constructed for these outcomes as functions of dose and subgroup. The model performs adaptive clustering of adjacent subgroups having similar dose‐outcome distributions to facilitate borrowing information across subgroups. To quantify toxicity‐efficacy risk‐benefit trade‐offs that may differ between subgroups, the objective function is based on outcome utilities elicited separately for each subgroup. In the context of the renal cancer trial, a design is constructed and a simulation study is presented to evaluate the design's reliability, safety, and robustness, and to compare it to designs that either ignore subgroups or run a separate trial within each subgroup.

     
    more » « less
  3. Abstract Overly restrictive eligibility criteria for clinical trials may limit the generalizability of the trial results to their target real-world patient populations. We developed a novel machine learning approach using large collections of real-world data (RWD) to better inform clinical trial eligibility criteria design. We extracted patients’ clinical events from electronic health records (EHRs), which include demographics, diagnoses, and drugs, and assumed certain compositions of these clinical events within an individual’s EHRs can determine the subphenotypes—homogeneous clusters of patients, where patients within each subgroup share similar clinical characteristics. We introduced an outcome-guided probabilistic model to identify those subphenotypes, such that the patients within the same subgroup not only share similar clinical characteristics but also at similar risk levels of encountering severe adverse events (SAEs). We evaluated our algorithm on two previously conducted clinical trials with EHRs from the OneFlorida+ Clinical Research Consortium. Our model can clearly identify the patient subgroups who are more likely to suffer or not suffer from SAEs as subphenotypes in a transparent and interpretable way. Our approach identified a set of clinical topics and derived novel patient representations based on them. Each clinical topic represents a certain clinical event composition pattern learned from the patient EHRs. Tested on both trials, patient subgroup (#SAE=0) and patient subgroup (#SAE>0) can be well-separated by k-means clustering using the inferred topics. The inferred topics characterized as likely to align with the patient subgroup (#SAE>0) revealed meaningful combinations of clinical features and can provide data-driven recommendations for refining the exclusion criteria of clinical trials. The proposed supervised topic modeling approach can infer the clinical topics from the subphenotypes with or without SAEs. The potential rules for describing the patient subgroups with SAEs can be further derived to inform the design of clinical trial eligibility criteria. 
    more » « less
  4. Abstract

    This article leverages a five-treatment response mode experiment (paper-only, web-only, sequential web-mail, choice, and choice-plus [choice with a promised incentive for responding online]) that was conducted within a nationally representative survey. Because this survey’s sample was drawn from respondents to another nationally representative survey, we have rich frame data that includes multiple indicators of comfort using the internet for our sample members and we can compare their response behavior across two surveys. We find that the paper-only treatment yielded a lower response rate than most of the other treatments, but there were not significant differences between the response rates for the other treatments. Among our mixed-mode treatments, the sequential web-mail treatment had the highest percentage of response by web and the lowest cost per response. When focusing on the subgroups that we expected to be the least—and the most—comfortable with the internet, we found that the paper-only treatment generally performed worse than the others, even among subgroups expected not to be comfortable with the internet. We generally did not find significant differences in the effect of response mode treatment on the response rate or percentage of response by web between the subgroups who were the most and least comfortable with the internet. In terms of the consistency of response mode choice over time, our results suggest that some people respond consistently—but also that response mode preferences are weak enough that they can be influenced by the way in which the modes are offered. We ultimately recommend using a sequential web-mail design to minimize costs while still providing people who cannot or will not respond by web with another response mode option. We also find evidence that there may be a growing lack of interest in responding by paper; more research is needed in this area.

     
    more » « less
  5. Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not as much as cytotoxic agents. The primary objectives of a cancer therapeutic vaccine phase I trial thus often include determining whether the vaccine shows biologic activity and the minimum dose necessary to achieve a full immune or even clinical response. In this paper, we propose a new Bayesian phase I trial design that allows simultaneous evaluation of safety and immunogenicity outcomes. We demonstrate the proposed clinical trial design by both a numeric study and a therapeutic human papillomavirus vaccine trial.

     
    more » « less